drugset / Trial / NCT03272165
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
Phase 1
Completed
50 enrolled
AstraZeneca
Catalent · collabCovance · collabMMS Holdings, Inc · collabTakeda · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants. Each participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled assessments over a period of 13 weeks. The main aim of the study is to assess the safety and tolerability of single doses of MEDI1341 in healthy volunteers.
Timeline
- Start
- 2017-10-17
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INDENEBART | Monoclonal antibody | — | Intravenous |